Procedural and early clinical outcomes of patients with de novo coronary bifurcation lesions treated with the novel Nile PAX dedicated bifurcation polymer-free paclitaxel coated stents: results from the prospective, multicentre, non-randomised BIPAX clinical trial.

Aims: To demonstrate the acute and early outcomes of the novel Nile PAX dedicated polymer-free paclitaxel-coated stents (Minvasys SAS, Gennevilliers, France) in the treatment of de novo coronary bifurcation lesions.

Methods And Results: The Nile PAX device incorporates a cobalt-chromium alloy with a side aperture in the mid-stent designed to optimise scaffold at the bifurcation carina and side branch (SB) ostium, while maintaining SB access during procedure. From December 2008 to February 2010, 101 patients were prospectively enrolled in a non-randomised, multicentre study.

Integration of 3D reconstruction in the SELection criteria for Excessive Crossing Times for Magnetically Supported Percutaneous Coronary Intervention. SELECT-MP.

Aims: To develop a clinical prediction rule based on 3D reconstruction of coronary arteries that would prospectively identify lesions that are difficult to cross and could benefit from magnetic navigation.

Methods And Results: The coronary anatomy of a cohort of 120 lesions that had undergone percutaneous coronary intervention (derivation set) was analysed using 3D reconstruction for vessel and lesion characteristics. The crossing time was the total clock time to reach a satisfactory distal position after leaving the guiding catheter.